Bruce Gil

Harrow increased the cost of its eye medication Triesence from $161 to $944

Harvard professor Timothy Springer owns about 16% of Morphic, a company Eli Lilly is buying for $3.2 billion

HHS Secretary Kennedy says updated dietary guidelines will prioritize public health over special interests

U.S. brands face rising costs and potential price hikes as major suppliers — China and Vietnam — face steep levies

Plus: three ways Big Tech is vulnerable to tariff retaliation

The pharma giant just sued two compounding pharmacies for making off-brand versions of Zepbound

The digital healthcare platform announced Tuesday that it has added Zepbound and generic liraglutide to its platform

The state-owned brain chip company plans to implant its experimental device on at least 13 patients by the end of the year

Plus: Chipotle’s avocado hunt

Research shows a dramatic increase in GLP-1 prescriptions among people without diabetes; spending hit nearly $6 billion in 2022